Clinical Documentation in the 21st Century: Executive Summary of a Policy Position Paper From the American College of Physicians

• PDF

Position Papers | 13 January 2015

FREE ONLINE FIRST

Thomson Kuhn, MA; Peter Basch, MD; Michael Barr, MD, MBA; Thomas Yackel, MD, MPH, MS, for the Medical Informatics Committee of the American College of Physicians*

[+] Article and Author Information

See Also:

• Clinical Documentation to Improve Patient Care

Ann Intern Med. Published online 13 January 2015 doi:10.7326/M14-2128

Amoxicillin rash in patients with infectious mononucleosis: evidence of true drug sensitization

Short report

Katinka Ónodi-Nagy, Ágnes Kinyó, Angéla Meszes, Edina Garaczi, Lajos Kemény and Zsuzsanna Bata-Csörg¿

Allergy, Asthma & Clinical Immunology 2015, 11:1  doi:10.1186/1710-1492-11-1

Published: 9 January 2015

Abstract (provisional)

Background

It hasn't been clearly understood yet whether sensitization to antibiotics, the virus itself or transient loss of drug tolerance due to the virus, is responsible for the development of maculopapular exanthems following amoxicillin intake in patients with infectious mononucleosis. We aimed to examine whether sensitization to penicillin developed among patients with skin rash following amoxicillin treatment within infectious mononucleosis.

Allergy to sunflower seed and sunflower butter as proposed vehicle for sensitization

Case report

Elana Lavine^1* and Moshe Ben-Shoshan²

Allergy, Asthma & Clinical Immunology 2015, 11:2  doi:10.1186/s13223-014-0065-6

Published: 8 January 2015

Abstract (provisional)

Background

It is hypothesized that household exposure to allergenic proteins via an impaired skin barrier, such as atopic dermatitis, may contribute to the development of IgE sensitization. Household presence of peanut is a risk factor for the development of peanut allergy in children. Sunflower seed butter is a peanut-free alternative to peanut butter, and sunflower seed allergy is an uncommon but reported entity.

The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial

Immunology Letters

Volume 162, Issue 2, Part B, December 2014, Pages 185–193

Dutch Society for Immunology 1964 – 2014 — Special issue on the occasion of the 50th anniversary of the Dutch Society for Immunology (NVVI)

• Fulvio Braido^a, 
• Giovanni Melioli^a, , , 
• Piero Candoli^b, 
• Andrea Cavalot^c, 
• Mario Di Gioacchino^d, 
• Vittorio Ferrero^e, 
• Cristoforo Incorvaia^f, 
• Carlo Mereu^g, 
• Erminia Ridolo^h, 
• Giovanni Rollaⁱ, 
• Oliviero Rossi^j, 
• Eleonora Savi^k, 
• Libero Tubino^l, 
• Giorgio Reggiardo^m, 
• Ilaria Baiardini^a, 
• Eddi di Marcoⁿ, 
• Gilberto Rinaldi^o, 
• Giorgio Walter Canonica^a, 
• Lantigen Study Group, 
• Carlo Accorsi^c, 
• Claudia Bossilinoⁱ, 
• Laura Bonzano^h, 
• Michela DiLizia^d, 
• Barbara Fedrighini^c, 
• Valentina Garelli^a, 
• Vincenzo Gerace^l, 
• Sara Maniscalco^g, 
• Ilaria Massaro^j,
• Alessandro Messi^b, 
• Manlio Milanese^g, 
• Silvia Peveri^k, 
• Arminio Penno^c,

 Show more

doi:10.1016/j.imlet.2014.10.026

Get rights and content

Under a Creative Commons license

  Open Access

---

Highlights

•

Old trials on LantigenB (LB) showed its effect on recurrent respiratory infections.

•

These studies were performed using non-updated clinical and statistical methods.

•

Here we show that LB reduces the number of infections in a phase IV clinical study.

•

LB represents a real first-line prophylaxis of recurrent respiratory infections.

The Impact of Double-Blind Placebo-Controlled Food Challenge (DBPCFC) on the Socioeconomic Cost of Food Allergy in Europe

I Cerecedo,1* J Zamora,2* M Fox,3 J Voordouw,4 N Plana,5 E Rokicka,6 M Fernandez-Rivas,7 S Vázquez Cortés,7 M Reche,8 A Fiandor,8 M Kowalski,9 G Antonides,10 M Mugford,11 LJ Frewer,4 B de la Hoz1

1Servicio de Alergología, Hospital Universitario Ramón y Cajal, Madrid, Spain 2Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal, CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain 3University of East Anglia, Health Economics Group, School of Medicine, Health Policy and Practice, Norwich, UK 4Wageningen University, Marketing and Consumer Behaviour Group, Wageningen, The Netherlands 5CIBER de Epidemiología y Salud Pública (CIBERESP), Unidad de Bioestadística Clínica, Hospital Universitario Ramón y Cajal, Madrid, Spain 6University of Lodz, Institute of Sociology, Lodz, Poland 7Servicio de Alergología, Hospital Universitario Clínico San Carlos, Madrid, Spain 8Servicio de Alergología, Hospital Universitario La Paz, Madrid, Spain 9Lodz University, Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Lodz, Poland 10Wageningen University, Economics of Consumers and Households group, Wageningen, The Netherlands 11University of East Anglia, Health Economics Group, School of Medicine, Health Policy and Practice, Norwich, UK *These authors contributed equally to this study

J Investig Allergol Clin Immunol 2014; Vol. 24(6): 418-424

Abstract Background: Double-blind placebo controlled food challenge (DBPCFC) is the gold standard diagnostic test in food allergy because it minimizes diagnostic bias. Objective: To investigate the potential effect of diagnosis on the socioeconomic costs of food allergy. Methods: A prospective longitudinal cost analysis study was conducted in Spain and Poland within the EuroPrevall project. Food-allergic patients were enrolled into the study and in all cases diagnosis was confirmed through a standardized DBPCFC. Data were collected through a self-administered survey on all aspects of health and social care resource use, costs of living, and costs of leisure activities. Costs were measured before and 6 months after the DBPCFC and reported in international dollars with 2007 as the benchmark year. Results: Forty-two patients were enrolled. Twenty-one patients had a negative DBPCFC and the suspected food was reintroduced into their diet. Comparing total direct costs before and after the DBPCFC, the reactive group spent a significantly higher amount (median increase of $813.1 over baseline), while the tolerant group’s spending decreased by a median of $87.3 (P=.031). The amount of money spent on food 6 months after diagnosis was also significantly higher in the reactive group (P=.040). Finally, a larger, but not statistically significant, decrease in total indirect costs was observed in the tolerant group compared with the reactive group ($538.3 vs $32.3). Conclusion: DBPCFC has an impact on indirect and direct costs of living. The main contribution to this increase was money spent on food. Key words: Food allergy. Double-Blind Placebo-Controlled Food Challenge. Diagnosis. Socioeconomic impact.   Free Full-Text (PDF)   How to use PDF documents

The relationship between allergy and asthma control, quality of life, and emotional status in patients with asthma: a cross-sectional study

Research

Hikmet Coban¹ and Yusuf Aydemir^12*

Allergy, Asthma & Clinical Immunology 2014, 10:67  doi:10.1186/s13223-014-0067-4

Published: 21 December 2014

Abstract (provisional)

Background 

Psychiatric comorbidities are prevalent in patients with chronic somatic disorders such as asthma. But, there is no clear evidence regarding the effect of atopic status and the type of sensitized allergen on emotional status. The aim of the present study was to investigate the effects of house dust mites and pollen allergies on emotional status, asthma control and the quality of life in patients with atopic asthma.

Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults

1. Marie-Christine Dombret1,8, 
2. Khuder Alagha2,8, 
3. Louis Philippe Boulet3,
4. Pierre Yves Brillet4, 
5. Guy Joos5, 
6. Michel Laviolette3, 
7. Renaud Louis6,
8. Thierry Rochat7, 
9. Paola Soccal7, 
10. Michel Aubier1 and 
11. Pascal Chanez2⇑

+Author Affiliations

1. ¹Dept of Respiratory Medicine, Bichat APHP, U700 INSERM University Hospitals Dept, Diderot University, Paris, France ²Dept of Respiratory Medicine, APHM, INSERM U1067 CNRS UMR 7333, Aix Marseille University, Marseille, France³Research Centre at the Institute of Cardiology and Respiratory Medicine, Laval University, Quebec, QC, Canada⁴Dept of Radiology, Avicenne Public Hospital, Bobigny, France ⁵Dept of Respiratory Medicine, Ghent University Hospital, Ghent University, Ghent, Belgium⁶Dept of Respiratory Medicine, Liege University Hospital, GIGAI3 Research Group, University of Liège, Liège, Belgium⁷Dept of Respiratory Medicine, HUG Geneva, Switzerland⁸Both authors contributed equally

1. Pascal Chanez, Dept of Respiratory Medicine, Marseille Public Hospitals, INSERM U1067 CNRS UMR 7333, Aix Marseille University, Hôpital Nord, 13015 Marseille, France. E-mail: pascal.chanez@univ-amu.fr
2. 
   
3. Abstract

Bronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment. It is an innovative treatment whose clinical efficacy and safety are beginning to be better understood.

Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults

Tristetraprolin and its Role in Regulation of Airway Inflammation

Molecular Pharmacology November 26, 2014mol.114.095984

Pavan Prabhala and 

Alaina Ammit*

+Author Affiliations

1. University of Sydney

1. ↵* Corresponding author; email: alaina.ammit@sydney.edu.au

Abstract

Chronic inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are clinically and socio-economically important diseases globally. Currently the mainstay of anti-inflammatory therapy in respiratory diseases is corticosteroids.